中久保 祥 (ナカクボ シヨウ)

北海道大学病院 感染制御部助教
総合イノベーション創発機構ワクチン研究開発拠点助教

研究者基本情報

■ 学位
  • 医学博士, 北海道大学, 2020年03月
■ URL
researchmap URLホームページURL■ ID 各種
ORCID IDJ-Global ID■ 研究キーワード・分野
研究分野
  • ライフサイエンス, 感染症内科学, COVID-19, 肺炎球菌, microbiome, metabolome
■ 担当教育組織

経歴

■ 経歴
経歴
  • 2021年 - 現在
    北海道大学病院 感染制御部, 助教
  • 2020年10月 - 2020年12月
    北海道大学医学研究院呼吸器内科学教室, 助教
  • 2017年04月 - 2019年03月
    東邦大学医学部微生物感染症学講座, 特別研究員
学歴
  • 2020年03月, 北海道大学医学研究院, 博士(医学)
  • 2009年03月, 北海道大学, 医学部, 医学科

研究活動情報

■ 受賞
  • 2024年06月, 日本感染症学会, 北里柴三郎記念学術奨励賞
    Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study
  • 2024年03月, 北海道大学医学研究院, 優秀論文賞
    Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study
  • 2023年02月, 北海道大学医学部同窓会, フラテ研究奨励賞
    北海道大学病院におけるCOVID-19診療経験から導きだされた一連の臨床研究
    中久保 祥
■ 論文
  • Successful Liver Transplantation Under Antimicrobial Therapy in a Patient With Preexisting Pulmonary Mycobacterium avium Complex Disease
    Masaaki Watanabe; Sho Nakakubo; Akinobu Taketomi
    Transplant Infectious Disease, 2026年08月03日
    研究論文(学術雑誌)
  • Characterization of mucus plugging in patients with chronic obstructive pulmonary disease: additional clinical significance of asthma-like features
    Kaoruko Shimizu; Naoya Tanabe; Susumu Sato; Shotaro Chubachi; Kazuya Tanimura; Naoya Fujino; Hiroaki Iijima; Nobuyasu Wakazono; Isao Yokota; Yuki Abe; Keisuke Kamada; Sho Nakakubo; Hirokazu Kimura; Houman Goudarzi; Takeshi Hattori; Ichizo Tsujino; Hironi Makita; Masaharu Nishimura; Satoshi Konno
    BMC Pulmonary Medicine, Springer Science and Business Media LLC, 2026年07月06日, [査読有り]
    研究論文(学術雑誌)
  • Association between FDG accumulation in interstitial lesions and acute exacerbation risk in lung cancer: multicenter analysis.
    Yuriko Ishida; Shiro Watanabe; Jun Sakakibara-Konishi; Yasuyuki Ikezawa; Hajime Kikuchi; Yasutaka Kawai; Hirokazu Kimura; Sho Nakakubo; Kenji Hirata; Kohsuke Kudo; Satoshi Konno
    Japanese journal of radiology, 44, 1, 147, 155, 2026年01月, [国内誌]
    英語, 研究論文(学術雑誌), PURPOSE: Interstitial pneumonia (IP) is associated with poor prognosis in lung cancer and increases the risk of acute exacerbation (AE). Few studies analyzed the relationship between fluorodeoxyglucose (FDG) accumulation in IP with lung cancer complicated with IP and the incidence of AE. This study investigates the association between FDG accumulation in the interstitial lesions and the AE incidence in patients with lung cancer complicated with IP. MATERIALS AND METHODS: This multicenter, retrospective study included patients with lung cancer complicated with IP who received chemotherapy. All CTs at baseline and the onset of AE were centrally adjudicated. The SUVpeak and FDGscore for interstitial lesions were calculated from FDG positron emission tomography images before chemotherapy, and these values were corrected using reference uptake. To determine the association with AE risk, clinical characteristics and imaging findings were compared between patients who developed AE and those who did not. Subsequently, logistic regression analysis was performed to identify risk factors for the development of AE. RESULTS: One hundred and thirteen patients who met the eligibility criteria were enrolled from three centers. However, 9 patients with a clinical diagnosis of collagen-related interstitial pneumonia were excluded due to predominant FDG accumulation in the interstitial lesions, and 104 patients were analyzed. Of those patients, 31.7% (33/104) developed all grade AE and 18.3% (19/104) developed grade 3 or higher. There were no significant differences in patient characteristics and imaging patterns between those with and without AE. SUVpeak in the ipsilateral and contralateral interstitial lesions to the tumor and the FDGscore did not differ between those with or without AE. CONCLUSIONS: No association was observed between FDG accumulation in interstitial lesions and AE in patients with lung cancer complicated with IP. We may have to remain cautious about the risk of AE in lung cancer complicated with IP, even when FDG accumulation in interstitial lesions is high or low.
  • Insights from wastewater surveillance into testing-related underreporting and hospital-acquired SARS-CoV-2 infections.
    Michio Murakami; Nobuhisa Ishiguro; Hiroki Ando; Mutsumi Ishida; Toshihiro Hamada; Sho Nakakubo; Reiko Oyamada; Takahiro Hayashi; Yusuke Niinuma; Keisuke Kagami; Tatsuya Fukumoto; Keisuke Taki; Tomoyuki Endo; Masaaki Kitajima
    Environment international, 207, 110028, 110028, 2026年01月, [国際誌]
    英語, 研究論文(学術雑誌), Wastewater surveillance for monitoring infections faces challenges due to discrepancies with sentinel-confirmed cases. This study aimed to clarify how SARS-CoV-2 RNA concentrations in wastewater can reflect COVID-19 dynamics within a hospital. We first examined whether testing rates were associated with the discrepancy between RNA concentrations in City of Sapporo wastewater treatment plants and the infection cases at Hokkaido University Hospital over approximately four years. Then, we analyzed associations between wastewater RNA concentrations and incidences of new cases among hospital-acquired infections. Linear regression was performed using RNA concentrations as the main explanatory variables, with air temperature and variant strain types included as covariates; infected cases with and without correction for testing rates were deemed the outcome. Poisson regression was also conducted, with new hospital-acquired cases as another outcome. After COVID-19 was legally reclassified in Japan to the same category as seasonal influenza, hospital testing rates declined significantly, even though wastewater RNA remained high. Corrected community-acquired infection cases showed higher R2 values (0.80 [95% confidence interval: 0.77-0.84]) than non-correction (0.73 [0.65-0.80]). Hospital-acquired infection incidence was positively associated with RNA concentrations from one week prior (incidence risk rate: 2.45 [1.37-4.40]), and a log10 RNA concentration [copies/L] of 4.51 (4.03-4.99) corresponded to a 25% probability of new incidence. These findings emphasized that SARS-CoV-2 wastewater surveillance provides an objective and useful indicator of COVID-19 dynamics in a hospital independent of testing rates.
  • Evolving COVID-19 symptoms and the ongoing course of research.
    Sho Nakakubo
    The Lancet. Infectious diseases, 25, 3, 245, 246, 2025年03月, [国際誌]
    英語, 研究論文(学術雑誌)
  • Intestinal obstruction caused by disseminated mycobacterium avium complex disease following solid organ transplantation: a case report.
    Akane Mita; Sho Nakakubo; Yusuke Nishimura; Hideki Shima; Masaaki Watanabe; Tsuyoshi Shimamura; Satoshi Konno
    BMC infectious diseases, 25, 1, 120, 120, 2025年01月25日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Mycobacterium avium complex (MAC) is a common pathogen causing non-tuberculous mycobacterial infections, primarily affecting the lungs. Disseminated MAC disease occurs mainly in immunocompromised individuals, such as those with acquired immunodeficiency syndrome, hematological malignancies, or those positive for anti-interferon-γ antibodies. However, its occurrence in solid organ transplant recipients is uncommon. Herein, we report a rare case of disseminated MAC disease following liver transplantation, which led to an obstructive mass in the intestinal tract that required differentiation from a malignant tumor. CASE PRESENTATION: A 76-year-old woman, who had undergone living-donor liver transplantation 15 years earlier for primary biliary cirrhosis, presented with persistent fever and vomiting three months before admission. She had a history of pulmonary MAC diagnosed five years earlier but remained untreated due to stable lung lesions. Abdominal computed tomography (CT) during her current illness revealed new thickening at the jejuno-jejunal anastomosis site and enlarged mesenteric lymph nodes. Positron emission tomography-CT indicated increased uptake at these sites, suggesting a possible malignancy. Endoscopy revealed an elevated lesion with circumferential ulcers, leading to a suspicion of primary malignant lymphoma. However, biopsies showed CD68-positive histiocyte-like cells with numerous acid-fast bacilli, confirming disseminated MAC infection. Despite ongoing antimicrobial therapy, the patient's intestinal lesions persisted, and she required prolonged hospitalization and interventions for bile drainage and enteral nutrition. CONCLUSION: This case underscores the importance of considering disseminated MAC as a potential complication in solid organ transplant recipients, even when a long period has passed since transplantation. Disseminated MAC can mimic malignancy, presenting with significant lesions causing intestinal obstruction. Awareness and thorough differential diagnosis are essential for timely and accurate management in such complex cases. The patient's outcome emphasizes the need for vigilance in managing long-term immunosuppressed patients, particularly when they present with atypical infections.
  • 新型コロナウイルス感染を契機に増悪し大腸亜全摘を施行した潰瘍性大腸炎の1例
    長安 健; 藤好 直; 本間 重紀; 市川 伸樹; 吉田 雅; 柴田 賢吾; 松井 博紀; 桂田 武彦; 中久保 祥; 畑中 佳奈子; 武冨 紹信
    日本消化器外科学会雑誌, 57, 4, 204, 211, (一社)日本消化器外科学会, 2024年04月
    日本語
  • びまん性肺胞出血を呈したリンパ脈管筋腫症の一例
    木村 太俊; 武井 望; 小熊 昂; 堀井 洋志; 中村 順一; 中久保 祥; 木村 孔一; 鈴木 雅; 大高 和人; 加藤 達哉; 大川 紘弥; 松野 吉宏; 今野 哲
    日本呼吸器学会誌, 13, 増刊, 244, 244, (一社)日本呼吸器学会, 2024年03月
    日本語
  • Visible Bronchial Obstruction after Hematopoietic Stem Cell Transplantation.
    Takatoshi Suzuki; Sho Nakakubo; Masaru Suzuki; Satoshi Konno
    Internal medicine (Tokyo, Japan), 62, 21, 3255, 3256, 2023年11月01日, [国内誌]
    英語, 研究論文(学術雑誌)
  • Factors associated with household transmission of SARS-CoV-2 omicron variant to health care workers: A retrospective cohort study.
    Keisuke Kagami; Reiko Oyamada; Tsubasa Watanabe; Sho Nakakubo; Takahiro Hayashi; Sumio Iwasaki; Tatsuya Fukumoto; Takayuki Usami; Kasumi Hayasaka; Shinichi Fujisawa; Chiaki Watanabe; Mutsumi Nishida; Takanori Teshima; Yusuke Niinuma; Isao Yokota; Yoh Takekuma; Mitsuru Sugawara; Nobuhisa Ishiguro
    International journal of nursing practice, 29, 5, e13195, 2023年08月24日, [国際誌]
    英語, 研究論文(学術雑誌), AIM: The aim of this study was to determine the risk factors for household transmission of the omicron variant of SARS-CoV-2. BACKGROUND: The household infection rate has been reported to be higher for the omicron variant than for non-omicron variants of SARS-CoV-2. Determination of the risk factors for household transmission of the omicron variant is therefore important. DESIGN: A Retrospective Cohort Study was conducted. METHODS: When family members of health care workers (HCWs) were found to be infected with SARS-CoV-2, the HCWs had to receive two nucleic acid amplification tests for SARS-CoV-2: immediately after and 5 to 10 days after the onset of COVID-19 in the family members. Risk factors of household transmission were analysed by comparing cases (HCWs infected with SARS-CoV-2) and controls (HCWs not infected with SARS-CoV-2) using multivariable analysis. RESULTS: Unvaccinated status (OR: 3.97), age of index cases (≤6 years) (OR: 1.94) and staying at home with index cases (OR: 10.18) were risk factors for household transmission. CONCLUSION: If there is a strong desire to avoid household infection, family members infected with SARS-CoV-2 should live separately during the period of viral shedding.
  • Correlation between antibiotic use and resistance of gram-negative bacteria at a university hospital in Japan from 2013 to 2021: a study using the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system.
    Keisuke Kagami; Nobuhisa Ishiguro; Sumio Iwasaki; Keisuke Taki; Tatsuya Fukumoto; Kasumi Hayasaka; Reiko Oyamada; Tsubasa Watanabe; Sho Nakakubo; Yusuke Niinuma; Mitsuru Sugawara; Yoh Takekuma
    European journal of hospital pharmacy : science and practice, 2023年07月12日, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: The Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system aggregates information related to antimicrobial resistance (AMR) measures. We aimed to investigate the correlation between antibiotic use and AMR at a university hospital from 2013 to 2021 in a time series analysis using the J-SIPHE system. We also studied this correlation in each ward (inter-ward analysis). METHODS: Data on antibiotic use and resistance rates were collected from the J-SIPHE system, except for the resistance rate in each ward, which was calculated from the source data prepared for this system. RESULTS: Piperacillin/tazobactam use was positively correlated with piperacillin/tazobactam resistance in Escherichia coli and Klebsiella pneumoniae in the inter-ward analysis, and in Pseudomonas aeruginosa in both analyses. Carbapenem use was positively correlated with meropenem resistance in Enterobacter cloacae in the time series analysis and in P. aeruginosa in both analyses, and imipenem/cilastatin resistance in P. aeruginosa in inter-ward analysis. Quinolone use was positively correlated with levofloxacin resistance in E. coli in both analyses, and in K. pneumoniae in inter-ward analysis. CONCLUSIONS: This is the first study to investigate the correlation between antibiotic use and AMR at a single hospital in time series and inter-ward analyses using the J-SIPHE system and data prepared for this system, suggesting that this system may be useful for promoting AMR measures.
  • Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
    Sho Nakakubo; Naoki Kishida; Kenichi Okuda; Keisuke Kamada; Masami Iwama; Masaru Suzuki; Isao Yokota; Yoichi M Ito; Yasuyuki Nasuhara; Richard C Boucher; Satoshi Konno
    The Lancet. Infectious diseases, 2023年06月30日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Previous SARS-CoV-2 infection and vaccination, coupled with the rapid evolution of SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We aimed to characterise the clinical symptoms of COVID-19 individuals in omicron BA.2 and BA.5 Japanese pandemic periods to identify omicron and subvariant associations between symptoms, immune status, and clinical outcomes. METHODS: In this registry-based observational study, individuals registered in Sapporo's web-based COVID-19 information system entered 12 pre-selected symptoms, days since symptom onset, vaccination history, SARS-CoV-2 infection history, and background. Eligibility criteria included symptomatic individuals who tested positive for SARS-CoV-2 (PCR or antigen test), and individuals who were not tested for SARS-CoV-2 but developed new symptoms after a household member tested positive for SARS-CoV-2. Symptom prevalence, variables associated with symptoms, and symptoms associated with progression to severe disease were analysed. FINDINGS: Data were collected and analysed between April 25 and Sept 25, 2022. For 157 861 omicron-infected symptomatic individuals, cough was the most common symptom (99 032 [62·7%] patients), followed by sore throat (95 838 [60·7%] patients), nasal discharge (69 968 [44·3%] patients), and fever (61 218 [38·8%] patients). Omicron BA.5 infection was associated with a higher prevalence of systemic symptoms than BA.2 in vaccinated and unvaccinated individuals (adjusted odds ratio [OR] for fever: 2·18 [95% CI 2·12-2·25]). Omicron breakthrough-infected individuals with three or more vaccinations or previous infection were less likely to exhibit systemic symptoms (fever 0·50 [0·49-0·51]), but more likely to exhibit upper respiratory symptoms (sore throat 1·33 [1·29-1·36]; nasal discharge 1·84 [1·80-1·89]). Infected older individuals (≥65 years) had lower odds for all symptoms. However, when symptoms were manifest, systemic symptoms were associated with increased odds for severe disease (dyspnoea 3·01 [1·84-4·91]; fever 2·93 [1·89-4·52]), whereas upper respiratory symptoms were associated with decreased odds (sore throat 0·38 [0·24-0·63]; nasal discharge 0·48 [0·28-0·81]). INTERPRETATION: Host immunological status, omicron subvariant, and age were associated with a spectrum of COVID-19 symptoms and outcomes. BA.5 produced a higher systemic symptom prevalence than BA.2. Vaccination and previous infection reduced systemic symptom prevalence and improved outcomes but increased upper respiratory tract symptom prevalence. Systemic, but not upper respiratory, symptoms in older people heralded severe disease. Our findings could serve as a practical guide to use COVID-19 symptoms to appropriately modify health-care strategies and predict clinical outcomes for older patients with omicron infections. FUNDING: Japan Agency for Medical Research and Development.
  • Pseudotumor of the skin due to Mycobacterium genavense.
    Suguru Kurosawa; Keisuke Imafuku; Sho Nakakubo; Sumio Iwasaki; Takanori Teshima; Hideki Goto; Hideyuki Ujiie
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023年05月15日, [国際誌]
    英語, Mycobacterium genavense is a rare type of non-tuberculous mycobacterium (NTM) that has been reported to cause disseminated infections in immunocompromised patients. Because M. genavense is slow-growing and poorly able to form colonies on Ogawa's medium, genetic and molecular analyses are necessary to identify this pathogen. NTM infections present with various cutaneous manifestations. Of these, rare cases have been reported to present with mycobacterial pseudotumors. However, there are no reports of M. genavense with cutaneous pseudotumors. In this paper, we report a case of a pseudotumor due to M. genavense infection that was observed only in a cutaneous lesion. The patient was taking 5 mg of prednisolone and was aware of a tumor on the right lower leg. Biopsy samples showed diffuse spindle-shaped histiocytes and various other inflammatory cell infiltrates, and Ziehl-Neelsen staining detected mycobacterium. Since no colonies formed on Ogawa medium, genetic testing was performed, and M. genavense was identified by DNA sequence analysis. There were no other disseminated lesions beyond the skin, including in the lungs and liver. Since the patient was immunosuppressed, in accordance with previous literature, a combination therapy of clarithromycin, ethambutol, and rifampicin for 4 months was recommended. When no growth is observed on Ogawa's medium in cases of infection, it is essential to identify the infectious pathogen by genetic analysis.
  • Mycobacterium genavenseによる限局性の皮膚感染症を呈した1例
    黒澤 卓; 今福 恵輔; 宮澤 元; 中久保 祥; 岩崎 澄央; 後藤 秀樹; 豊嶋 崇徳; 氏家 英之
    日本臨床皮膚科医会雑誌, 40, 3, 470, 470, 日本臨床皮膚科医会, 2023年05月
    日本語
  • 新型コロナウイルス感染をきっかけに増悪し大腸亜全摘に至った潰瘍性大腸炎の一例
    長安 健; 藤好 直; 本間 重紀; 市川 伸樹; 吉田 雅; 柴田 賢吾; 松井 博紀; 八木 駿; 武冨 紹信; 中久保 祥; 畑中 佳奈子
    日本外科学会定期学術集会抄録集, 123回, RS, 3, (一社)日本外科学会, 2023年04月
    日本語
  • Serum Lactate Dehydrogenase Level One Week after Admission Is the Strongest Predictor of Prognosis of COVID-19: A Large Observational Study Using the COVID-19 Registry Japan.
    Sho Nakakubo; Yoko Unoki; Koji Kitajima; Mari Terada; Hiroyuki Gatanaga; Norio Ohmagari; Isao Yokota; Satoshi Konno
    Viruses, 15, 3, 2023年03月02日, [国際誌]
    英語, 研究論文(学術雑誌), Clinical features of COVID-19 are diverse, and a useful tool for predicting clinical outcomes based on clinical characteristics of COVID-19 is needed. This study examined the laboratory values and trends that influence mortality in hospitalised COVID-19 patients. Data on hospitalised patients enrolled in a registry study in Japan (COVID-19 Registry Japan) were obtained. Patients with records on basic information, outcomes, and laboratory data on the day of admission (day 1) and day 8 were included. In-hospital mortality was set as the outcome, and associated factors were identified by multivariate analysis using the stepwise method. A total of 8860 hospitalised patients were included. The group with lactate dehydrogenase (LDH) levels >222 IU/L on day 8 had a higher mortality rate compared to the group with LDH levels ≤222 IU/L. Similar results were observed in subgroups formed by age, body mass index (BMI), underlying disease, and mutation type, except for those aged <50 years. When age, sex, BMI, underlying disease, and laboratory values on days 1 and 8 were tested for factors strongly associated with in-hospital mortality, LDH on day 8 was most strongly associated with mortality. LDH level on day 8 was the strongest predictor of in-hospital mortality in hospitalised COVID-19 patients, indicating its potential usefulness in post-treatment decision-making in severe COVID-19 cases.
  • Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan.
    Sho Nakakubo; Naoki Kishida; Kenichi Okuda; Keisuke Kamada; Masami Iwama; Masaru Suzuki; Isao Yokota; Yoichi M Ito; Yasuyuki Nasuhara; Richard C Boucher; Satoshi Konno
    medRxiv : the preprint server for health sciences, 2023年02月07日, [国際誌]
    英語, BACKGROUND: Previous SARS-CoV-2 infection and vaccination, coupled to rapid evolution of SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We characterized clinical symptoms of COVID-19 individuals in omicron BA.2 and BA.5 Japanese pandemic periods to identify omicron and subvariant associations between symptoms, immune status, and clinical outcomes. METHODS: Individuals registered in Sapporo's web-based COVID-19 information system entered 12 pre-selected symptoms, days since symptom onset, vaccination history, SARS-CoV-2 infection history, and background. Symptom frequencies, variables associated with symptoms, and symptoms associated with progression to severe disease were analysed. RESULTS: For all omicron-infected individuals, cough was the most common symptom (62.7%), followed by sore throat (60.7%), nasal discharge (44.3%), and fever (38.8%). Omicron BA.5 infection was associated with a higher symptom burden than BA.2 in vaccinated and unvaccinated individuals. Omicron breakthrough-infected individuals with ≥ 3 vaccinations or previous infection were less likely to exhibit systemic symptoms, but more likely to exhibit upper respiratory symptoms. Infected elderly individuals had lower odds for all symptoms, but, when symptoms were manifest, systemic symptoms were associated with an increased risk, whereas upper respiratory symptoms with a decreased risk, of severe disease. CONCLUSION: Host immunological status, omicron subvariant, and age were associated with a spectrum of COVID-19 symptoms and outcomes. BA.5 produced a greater symptom burden than BA.2. Vaccination and prior infection mitigated systemic symptoms and improved outcomes, but increased upper respiratory tract symptom burden. Systemic, but not upper respiratory, symptoms in the elderly heralded severe disease.
  • Breaking away from an endemic state of multidrug-resistant Pseudomonas aeruginosa by daily sink disinfection.
    Sumio Iwasaki; Rikako Sato; Keisuke Kagami; Kouji Akizawa; Kasumi Hayasaka; Tatsuya Fukumoto; Keisuke Taki; Yusuke Niinuma; Takehiro Yamada; Reiko Oyamada; Tsubasa Watanabe; Sho Nakakubo; Chiaki Watanabe; Takanori Teshima; Nobuhisa Ishiguro
    Antimicrobial stewardship & healthcare epidemiology : ASHE, 3, 1, e209, 2023年, [国際誌]
    英語, 研究論文(学術雑誌), The detection rate of multidrug-resistant Pseudomonas aeruginosa in patients admitted to 2 wards and the intensive care unit decreased from 20.3% (129 of 636 isolates) to 4.2% (37 of 889 isolates) after the start of disinfection of hand washing sinks using alkyl diaminoethylglycine hydrochloride.
  • Listeria monocytogenes bacteremia mimicking the systemic metastasis of adrenal cancer: a case report
    Yuki Hatakeyama; Sho Nakakubo; Hirotaka Kusaka; Naomi Watanabe; Yukinori Yoshida; Hitoshi Shinzaki; Hiromitsu Hiroumi; Naoki Kishida; Satoshi Konno
    BMC Infectious Diseases, 2022年10月15日
    研究論文(学術雑誌)
  • COVID-19肺炎治療中に冠攣縮性狭心症を発症した褐色細胞腫の一例
    宮本 麻唯子; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 中久保 祥; 佐藤 琢真; 松本 隆児; 大塚 拓也; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, 98, 2, 597, 597, (一社)日本内分泌学会, 2022年10月
    日本語
  • COVID-19肺炎治療中に冠攣縮性狭心症を発症した褐色細胞腫の一例
    宮本 麻唯子; 亀田 啓; 宮 愛香; 野本 博司; 曹 圭龍; 中村 昭伸; 中久保 祥; 佐藤 琢真; 松本 隆児; 大塚 拓也; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, 98, 2, 597, 597, (一社)日本内分泌学会, 2022年10月
    日本語
  • Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
    Yuichi Kojima; Sho Nakakubo; Keisuke Kamada; Yu Yamashita; Nozomu Takei; Junichi Nakamura; Munehiro Matsumoto; Hiroshi Horii; Kazuki Sato; Hideki Shima; Masaru Suzuki; Satoshi Konno
    Journal of medical virology, 94, 12, 5702, 5712, 2022年08月02日, [国際誌]
    英語, 研究論文(学術雑誌), Immunomodulators (tocilizumab/baricitinib) improve outcomes of coronavirus disease (COVID-19) patients, but the synergistic effect of remdesivir is unknown. The effect of combination therapy with remdesivir, immunomodulators, and standard treatment in COVID-19 patients was investigated. This retrospective, single-center study included COVID-19 patients who were treated with tocilizumab or baricitinib. The severity of respiratory status in the two groups on day 14 and day 28 and the duration to respiratory recovery in both groups were compared, and the effect of remdesivir use on respiratory status was examined in a multivariate analysis. Ninety-eight patients received tocilizumab or baricitinib; among them, 72 used remdesivir (remdesivir group) and 26 did not (control group). The remdesivir group achieved faster respiratory recovery than the control group (median 11 days vs. 21 days, p=0.033), faster weaning from supplemental oxygen (HR 2.54, 95% CI 1.14-5.66, p=0.021). Age, body mass index, diabetes mellitus, and time from onset to oxygen administration were independent prognostic factors. The remdesivir group achieved better severity level at days 14 and 28 (p=0.033 and 0.003, respectively) and greater improvement from baseline severity (p=0.047 and 0.018, respectively). Remdesivir combination therapy did not prolong survival (HR 0.31, 95% CI 0.04-2.16, p=0.23). Among severely ill COVID-19 patients who received immunomodulator, remdesivir contributed to a shorter respiratory recovery time and better respiratory status at days 14 and 28. Concomitant remdesivir with immunomodulators and standard treatment may provide additional benefit in improving respiratory status of COVID-19 patients. This article is protected by copyright. All rights reserved.
  • An Adult Case of Unilateral Left Pulmonary Artery Agenesis Presenting with Hemoptysis.
    Yuriko Ishida; Masaru Suzuki; Hiroshi Horii; Junichi Nakamura; Munehiro Matsumoto; Sho Nakakubo; Takahiro Sato; Ichizo Tsujino; Ryo Morita; Daisuke Abo; Satoshi Konno
    Internal medicine (Tokyo, Japan), 62, 5, 763, 767, 2022年07月22日, [国内誌]
    英語, 研究論文(学術雑誌), Pulmonary artery agenesis (PAA) is a rare congenital vascular anomaly usually diagnosed during infancy. We herein report a 67-year-old man with PAA manifesting as massive hemoptysis. Contrast-enhanced computed tomography of the chest revealed the diagnosis of PAA, which we speculated to have resulted in the present event. Detailed angiography provided more accurate information on the pulmonary vasculature and collateral circulation, which helped us plan tailored treatment. Although very rare, we must consider the possibility of PAA in adults with unexplained hemoptysis.
  • Correlation between antibiotic use and antibiotic resistance: A multicenter study using the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system in Hokkaido, Japan.
    Keisuke Kagami; Nobuhisa Ishiguro; Sumio Iwasaki; Takayuki Usami; Tatsuya Fukumoto; Kasumi Hayasaka; Reiko Oyamada; Tsubasa Watanabe; Sho Nakakubo; Yusuke Niinuma; Takashi Hagino; Yoshifumi Abe; Ikuya Fujimoto; Hideki Maekawa; Ryo Fujibayashi; Satoshi Fuke; Kuniko Asahi; Shuichi Ota; Tatsuya Nagakura; Toshinari Okubo; Hideomi Asanuma; Toshihiro Ito; Sho Okano; Erika Komatsu; Kota Sasaki; Kei Hashimoto; Kazutoshi Washiya; Yumiko Kato; Katsunori Kusumi; Yasufumi Asai; Yuichi Saito; Yoshiyuki Sakai; Minoru Sakurada; Yuji Sakimoto; Yukari Ichikawa; Takahiro Kinebuchi; Dai Kondo; Syuhei Kanno; Minoru Kobayashi; Kagami Hirabayashi; Shinako Saitou; Katsuhiko Saito; Yuuki Ebina; Yuusuke Koshizaki; Makoto Chiba; Atsushi Yasuda; Toshiya Sato; Atsuo Togashi; Takashi Abe; Takahiro Fujita; Kengo Umehara; Masaru Amishima; Nobuo Murakami; Tetsuya Yagi; Shuhei Fujimoto; Taichi Tajima; Mitsuru Sugawara; Yoh Takekuma
    American journal of infection control, 51, 2, 163, 171, 2022年06月04日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system aggregates information related to antimicrobial resistance (AMR) measures in participating medical institutions nationwide and is intended to be used for promotion of AMR measures in participating facilities and their communities. This multicenter study aimed to determine the usefulness of the J-SIPHE system for evaluating the correlation between antibiotic use and antibiotic resistance in Hokkaido, Japan. METHODS: Data on antibiotic use and detection rate of major resistant Gram-negative bacteria at 19 hospitals in 2020 were collected from the J-SIPHE system, and data correlations were analyzed using JMP Pro. RESULTS: The detection rate of carbapenem-resistant Pseudomonas aeruginosa was significantly positively correlated with carbapenem use (Spearman's ρ = 0.551; P = 0.015). There were significant positive correlations between the detection rate of fluoroquinolone-resistant Escherichia coli and the use of piperacillin/tazobactam, carbapenems, and quinolones [ρ = 0.518 (P = 0.023), ρ = 0.76 (P < 0.001), and ρ = 0.502 (P = 0.029), respectively]. CONCLUSION: This is the first multicenter study to investigate the correlation between antibiotic use and antibiotic resistance using the J-SIPHE system. The results suggest that using this system may be beneficial for promoting AMR measures.
  • CLOT-COVID studyにおける大出血例の検討
    中村 順一; 辻野 一三; 児島 裕一; 島 秀起; 中久保 祥; 今野 哲
    静脈学, 33, 2, 146, 146, (一社)日本静脈学会, 2022年06月
    日本語
  • 今月の症例 両側滲出性胸水と全身浮腫で発症し、局所麻酔下胸腔鏡でサルコイドーシスと診断した1例
    篠崎 鮎香[臺]; 木村 孔一; 山下 優; 堀井 洋志; 佐藤 一紀; 中村 順一; 中久保 祥; 鎌田 啓佑; 鈴木 雅; 中里 信一; 松野 吉宏; 今野 哲
    日本内科学会雑誌, 111, 5, 984, 989, (一社)日本内科学会, 2022年05月
    日本語, 66歳男性。全身倦怠感、全身浮腫を主訴に、前医にて両側滲出性胸水を指摘され、精査目的に当科紹介入院となった。血液検査や画像検査、胸水検査では特異的所見を認めず、局所麻酔下の胸腔鏡検査にて胸膜に多発結節性病変を認め、病理組織像および気管支鏡検査所見より、サルコイドーシス(組織診断群)と診断された。経過中に眼症状は認めず、プレドニゾロンによる内服治療を開始したところ、全身浮腫や両側胸水は改善傾向にあった。
  • 今月の症例 両側滲出性胸水と全身浮腫で発症し、局所麻酔下胸腔鏡でサルコイドーシスと診断した1例
    篠崎 鮎香[臺]; 木村 孔一; 山下 優; 堀井 洋志; 佐藤 一紀; 中村 順一; 中久保 祥; 鎌田 啓佑; 鈴木 雅; 中里 信一; 松野 吉宏; 今野 哲
    日本内科学会雑誌, 111, 5, 984, 989, (一社)日本内科学会, 2022年05月, [査読有り]
    日本語
  • Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
    Yuichi Kojima; Sho Nakakubo; Nozomu Takei; Keisuke Kamada; Yu Yamashita; Junichi Nakamura; Munehiro Matsumoto; Hiroshi Horii; Kazuki Sato; Hideki Shima; Masaru Suzuki; Satoshi Konno
    Medicina (Kaunas, Lithuania), 58, 4, 2022年04月04日, [国際誌]
    英語, 研究論文(学術雑誌), Background and Objectives: Tocilizumab and baricitinib have been observed to improve the outcomes of patients with coronavirus disease 2019 (COVID-19). However, a comparative evaluation of these drugs has not been performed. Materials and Methods: A retrospective, single-center study was conducted using the data of COVID-19 patients admitted to Hokkaido University hospital between April 2020 and September 2021, who were treated with tocilizumab or baricitinib. The clinical characteristics of the patients who received tocilizumab were compared to those of patients who received baricitinib. Univariate and multivariate logistic regression analyses of the outcomes of all-cause mortality and improvement in respiratory status were performed. The development of secondary infection events was analyzed using the Kaplan-Meier method and the log-rank test. Results: Of the 459 patients hospitalized with COVID-19 during the study, 64 received tocilizumab treatment and 34 baricitinib treatment, and those 98 patients were included in the study. Most patients were treated with concomitant steroids and exhibited the same severity level at the initiation of drug treatment. When compared to each other, neither tocilizumab nor baricitinib use were associated with all-cause mortality or improvement in respiratory status within 28 days from drug administration. Conclusions: Age, chronic renal disease and early administration of TCZ or BRT from the onset of COVID-19 were independent prognostic factors for all-cause mortality, whereas anti-viral drug use and the severity of COVID-19 at baseline were associated with an improvement in respiratory status. Secondary infection-free survival rates of patients treated with tocilizumab and those treated with baricitinib did not significantly differ. The results suggest that both tocilizumab and baricitinib could be clinically equivalent agents of choice in treatment of COVID-19.
  • COVID-19改善後に発症した遅発性の器質化肺炎を経気管支クライオバイオプシーで診断した3例と文献的考察
    堀井 洋志; 中久保 祥; 鎌田 啓佑; 山下 優; 中村 順一; 松本 宗大; 佐藤 一紀; 森永 大亮; 鈴木 雅; 岡崎 ななせ; 高桑 恵美; 松野 吉宏; 今野 哲
    日本呼吸器学会誌, 11, 増刊, 169, 169, (一社)日本呼吸器学会, 2022年04月
    日本語
  • C-reactive protein level predicts need for medical intervention in pregnant women with SARS-CoV2 infection: A retrospective study.
    Ryutaro Yamamoto; Hiroshi Asano; Takeshi Umazume; Masato Takaoka; Kiwamu Noshiro; Yoshihiro Saito; Kinuko Nakagawa; Kentaro Chiba; Sho Nakakubo; Yasuyuki Nasuhara; Satoshi Konno; Hidemichi Watari
    The journal of obstetrics and gynaecology research, 48, 4, 938, 945, 2022年04月, [国際誌]
    英語, 研究論文(学術雑誌), AIM: To make effective use of the limited available hospital space during the Coronavirus disease 2019 (COVID-19) pandemic, we conducted this study to investigate the laboratory indices that identify pregnant women with SARS-CoV2 infection who require medical intervention. METHODS: We carried out a retrospective analysis of pregnant women positive for COVID-19 who were admitted to Hokkaido University Hospital from September 2020 to June 2021. Medical interventions included oxygen supplementation, systemic corticosteroids, or supplemental liquids to treat infection-related symptoms. RESULTS: Forty-two infected pregnant patients were admitted to the hospital, half of whom required medical intervention (n = 21). Fever, C-reactive protein (CRP), and platelet count are all associated with need for medical intervention. Of the 32 patients with a fever of ≥37.5°C on days 0-3 after onset of syndromes, 22 (69%) continued to have a fever on days 4-6, of which 19 (86.4%) required medical intervention. CRP level on days 4-6 predicted the presence or absence of medical intervention (area under the receiver operating characteristic curve = 0.913), with a sensitivity of 81% and specificity of 100% at a CRP cutoff of 1.28 mg/dL. CONCLUSIONS: The need for medical intervention in pregnant patients can be predicted with high accuracy using a CRP cutoff of 1.28 mg/dL on days 4-6 after onset of syndromes. The presence of fever also may be an easy marker for selecting subjects who need or will need therapeutic intervention. These could be an effective triage method to determine appropriate indications for the hospitalization of pregnant women in future outbreaks.
  • Delayed-onset Organizing Pneumonia Emerging after Recovery from Coronavirus Disease 2019: A Report of Three Cases Diagnosed Using Transbronchial Cryobiopsy and a Review of the Literature.
    Sho Nakakubo; Keisuke Kamada; Yu Yamashita; Junichi Nakamura; Munehiro Matsumoto; Hiroshi Horii; Kazuki Sato; Daisuke Morinaga; Masaru Suzuki; Nanase Okazaki; Emi Takakuwa; Yoshihiro Matsuno; Satoshi Konno
    Internal medicine (Tokyo, Japan), 61, 9, 1403, 1410, 2022年03月05日, [国内誌]
    英語, 研究論文(学術雑誌), We present three cases with an atypical clinical course of organizing pneumonia (OP) secondary to COVID-19. Three patients were discharged with satisfactory improvement after standard steroid therapy for COVID-19. Shortly after the completion of treatment, the patients experienced a flare-up of symptoms. Imaging results showed new lesions in the lungs. Transbronchial lung cryobiopsy showed histological findings consistent with OP in all cases. Steroids were administered, and a good therapeutic response was observed. This report is the first to describe pathologically confirmed OP that developed after recovery from COVID-19. Careful follow-up is advisable for patients who have recovered from COVID-19.
  • 新型コロナウイルス感染症におけるトシリズマブとバリシチニブの治療成績の検討
    児島 裕一; 中久保 祥; 鎌田 啓佑; 山下 優; 今野 哲; 武井 望; 中村 順一; 松本 宗大; 堀井 洋志; 佐藤 一紀; 島 秀起; 鈴木 雅
    感染症学雑誌, 96, 臨増, 113, 113, (一社)日本感染症学会, 2022年03月
    日本語
  • Progressive multifocal leukoencephalopathy with mild clinical conditions and detection of archetype-like JC virus in cerebrospinal fluid.
    Kosuke Iwami; Kazuo Nakamichi; Masaaki Matsushima; Azusa Nagai; Shinichi Shirai; Sho Nakakubo; Ikuko Takahashi-Iwata; Masafumi Yamada; Ichiro Yabe
    Journal of neurovirology, 27, 6, 917, 922, 2021年12月, [国際誌]
    英語, 研究論文(学術雑誌), Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system with a poor prognosis and is primarily caused by JC virus (JCV) with a mutation called prototype. We encountered a case of PML with moderate progression and analyzed the mutational patterns of JCV in the cerebrospinal fluid (CSF). A 19-year-old Japanese woman with mild neurological symptoms was diagnosed with combined immunodeficiency following pneumocystis pneumonia. Brain magnetic resonance imaging scan showed multiple brain lesions, and real-time polymerase chain reaction testing detected JCV in the CSF, leading to the diagnosis of PML. The disease course of PML was stable after administration of mefloquine and mirtazapine with immunoglobulin replacement therapy. In the JCV genome cloned from the patient CSF, DNA sequences of the gene encoding the capsid protein (VP1) and the non-coding control region exhibited small mutations. However, they were quite similar to those of the archetype JCV, which persists asymptomatically in healthy individuals. These findings provide insight into the mutational characteristics of JCV in PML with mild symptoms and progression.
  • Multiple introductions of SARS-CoV-2 B.1.1.214 lineages from mainland Japan preceded the third wave of the COVID-19 epidemic in Hokkaido.
    Takako Shimura; Kodai Abe; Toshiki Takenouchi; Mamiko Yamada; Hisato Suzuki; Makoto Suematsu; Sho Nakakubo; Keisuke Kamada; Satoshi Konno; Takanori Teshima; Kenjiro Kosaki
    Travel medicine and infectious disease, 44, 102210, 102210, 2021年11月22日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The third wave of the COVID-19 epidemic in the island of Hokkaido, the second largest island in Japan, began abruptly in October 2020. METHODS: We conducted a phylodynamic analysis of the SARS-CoV-2 genome sequences obtained from tertiary medical centers in the Greater Tokyo Area and Sapporo, the largest city in the island of Hokkaido, and genome sequences published by GISAID, an international SARS-CoV-2 genome database. We also analyzed the statistics on the person-nights of travelers in the island of Hokkaido from the Greater Tokyo Area in 2019 versus 2020. RESULTS: At least eight sub-lineages belonging to the B.1.1.214 lineage were introduced to the island of Hokkaido from the island of Honshu, the mainland of Japan from late July to November 2020, during the governmental travel promotion program. Five of the eight sub-lineages originated from the Greater Tokyo Area. Comparison of the monthly ratios of the person-nights of travelers in the island of Hokkaido from the Greater Tokyo Area in 2019 and 2020 revealed that the highest value occurred in October 2020. CONCLUSION: We contend that the Japanese governmental travel promotion program contributed to the introduction of the B.1.1.214 sub-lineages from the main island of Honshu to the island of Hokkaido, and drove the third wave in Hokkaido, even if we are unable to establish the causality.
  • Macrolide/fluoroquinolone-resistant Campylobacter jejuni-induced cellulitis in a patient with X-linked agammaglobulinaemia successfully treated with carbapenem.
    Joohyung Youh; Keisuke Imafuku; Teruki Yanagi; Sho Nakakubo; Yosuke Mai; Hideyuki Kosumi; Takuya Kawamura; Ken Muramatsu; Chihiro Shiiya; Ayame Kimura; Sota Itamoto; Masafumi Yamada; Hideyuki Ujiie
    Dermatologic therapy, 34, 6, e15176, 2021年11月, [国際誌]
    英語
  • 両側滲出性胸水と全身浮腫で発症し、局所麻酔下胸腔鏡でサルコイドーシスと診断した一例
    篠崎 鮎香; 木村 孔一; 山下 優; 堀井 洋志; 佐藤 一紀; 中村 順一; 中久保 祥; 鎌田 啓佑; 鈴木 雅; 中里 信一; 松野 吉宏; 山口 哲夫; 大橋 健一; 江石 義信; 今野 哲
    日本サルコイドーシス/肉芽腫性疾患学会雑誌, 41, サプリメント号, 67, 67, 日本サルコイドーシス, 2021年10月
    日本語
  • X連鎖無γグロブリン血症患者に発症した多剤耐性Campylobacter jejuniによる蜂窩織炎の1例
    劉 柱亨; 柳 輝希; 板本 想太; 木村 彩萌; 眞井 洋輔; 村松 憲; 今福 恵輔; 氏家 英之; 中久保 祥; 山田 雅文
    日本皮膚科学会雑誌, 131, 9, 2072, 2072, (公社)日本皮膚科学会, 2021年08月
    日本語
  • 新型コロナウイルス感染症が北海道内の病院・診療所の診療に与えた影響に関するアンケート調査
    齋藤 充史; 千葉 弘文; 服部 健史; 黒沼 幸治; 中久保 祥; 鎌田 啓佑; 田代 典夫; 田中 裕士; 福家 聡; 今野 哲
    日本呼吸器学会誌, 10, 3, 245, 250, (一社)日本呼吸器学会, 2021年05月
    日本語
  • 新型コロナウイルス感染症が北海道内の病院・診療所の診療に与えた影響に関するアンケート調査
    齋藤 充史; 千葉 弘文; 服部 健史; 黒沼 幸治; 中久保 祥; 鎌田 啓佑; 田代 典夫; 田中 裕士; 福家 聡; 今野 哲
    日本呼吸器学会誌, 10, 3, 245, 250, (一社)日本呼吸器学会, 2021年05月
    日本語
  • Effect of varying storage conditions on diagnostic test outcomes of SARS-CoV-2.
    Satoshi Oguri; Shinichi Fujisawa; Keisuke Kamada; Sho Nakakubo; Yu Yamashita; Junichi Nakamura; Hiroshi Horii; Kazuki Sato; Mutsumi Nishida; Takanori Teshima; Yoichi Ohiro; Ayato Takada; Satoshi Konno
    The Journal of infection, 83, 1, 119, 145, 2021年04月03日, [国際誌]
    英語
  • COVID-19肺炎を合併し、ブロック&リプレースにより高コルチゾール血症のコントロールを行った活動性クッシング病の1例
    湯野 暁子; 高橋 由華; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 山下 優; 中久保 祥; 鎌田 啓佑; 鈴木 雅; 井下 尚子; 今野 哲; 三好 秀明; 渥美 達也; 澤村 豊; 島津 章
    日本内分泌学会雑誌, 97, 1, 260, 260, (一社)日本内分泌学会, 2021年04月
    日本語
  • 血気胸を発症したPleuroparenchymal fibroelastosis(PPFE)合併肺癌の1切除例
    大塚 慎也; 加藤 達哉; 佐々木 明洋; 山崎 洋; 氏家 秀樹; 藤原 晶; 樋田 泰浩; 加賀 基知三; 若狭 哲; 中村 順一; 篠崎 鮎香; 中久保 祥; 木村 孔一; 渡辺 正明; 岡崎 ななせ; 松野 吉宏
    肺癌, 61, 1, 67, 67, (NPO)日本肺癌学会, 2021年02月
    日本語
  • 【COVID-19の病態・診断・治療 現場の知恵とこれからの羅針盤】(VI章)各施設はどのようにCOVID-19を診断・治療していたのか 各施設の対応 北海道大学病院
    中久保 祥; 今野 哲
    呼吸器ジャーナル, 別冊, 163, 167, (株)医学書院, 2021年01月
    日本語
  • Successful management of a patient with active Cushing‍'‍s disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
    Akiko Yuno; Yoshiyuki Kenmotsu; Yuka Takahashi; Hiroshi Nomoto; Hiraku Kameda; Kyu Yong Cho; Akinobu Nakamura; Yu Yamashita; Junichi Nakamura; Sho Nakakubo; Keisuke Kamada; Masaru Suzuki; Hirokazu Sugino; Naoko Inoshita; Satoshi Konno; Hideaki Miyoshi; Tatsuya Atsumi; Yutaka Sawamura; Akira Shimatsu
    Endocrine journal, 68, 4, 477, 484, 2020年12月24日, [国内誌]
    英語, 研究論文(学術雑誌), We provide the details of the successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. The patient was a 27-year-old Japanese female healthcare worker who was scheduled to undergo pituitary surgery for Cushing's disease. She had been in close contact with an undiagnosed patient infected with COVID-19 and then developed COVID-19 pneumonia. Despite a lack of known risk factors associated with severe COVID-19 infection, the patient's dyspnea worsened and her respiratory condition deteriorated, as indicated by the need for 7 L/min oxygen supply by mask to maintain her oxygen saturation at >90%. Medical treatment was initiated to control hypercortisolism by the 'block and replace' regimen using steroidogenesis inhibitors and hydrocortisone. The COVID-19 pneumonia improved with multi-modal treatment including antiviral therapy. One month later, after a negative severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) test result and with appropriate protection against virus transmission to medical staff in the operating room and daily medical care nurses, trans-sphenoidal surgery was performed by our highly experienced pituitary surgeon. One month after the surgery, the patient's basal ACTH and cortisol levels and urinary free cortisol were all under the detection limit. Surgical remission was expected. Since hypercortisolism due to active Cushing's disease may worsen a COVID-19 infection, multi-disciplinary management that includes appropriate and prompt treatment strategies is mandatory in such cases.
  • Proposal of COVID-19 Clinical Risk Score for the management of suspected COVID-19 cases: a case control study.
    Sho Nakakubo; Masaru Suzuki; Keisuke Kamada; Yu Yamashita; Junichi Nakamura; Hiroshi Horii; Kazuki Sato; Munehiro Matsumoto; Yuki Abe; Kosuke Tsuji; Nobuhisa Ishiguro; Yasuyuki Nasuhara; Satoshi Konno
    BMC infectious diseases, 20, 1, 858, 858, 2020年11月18日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: No clinical scoring system has yet been established to estimate the likelihood of coronavirus disease (COVID-19) and determine the suitability of diagnostic testing in suspected COVID-19 patients. METHODS: This was a single-center, retrospective, observational study of patients with suspected COVID-19 and confirmed COVID-19. Patient background, clinical course, laboratory and computed tomography (CT) findings, and the presence of alternative diagnoses were evaluated. Clinical risk scores were developed based on clinical differences between patients with and without COVID-19. RESULTS: Among 110 patients suspected of having COVID-19, 60.9% underwent polymerase chain reaction (PCR) testing based on the judgment of physicians. Two patients were found to have COVID-19. The clinical characteristics of 108 non-COVID-19 patients were compared with those of 23 confirmed COVID-19 patients. Patients with COVID-19 were more likely to have a history of high-risk exposures and an abnormal sense of taste and smell. The COVID-19 group had significantly higher rates of subnormal white blood cell counts, lower eosinophil counts, and lower procalcitonin levels than the non-COVID-19 group. When blood test results, CT findings, and the presence of alternative diagnoses were scored on an 11-point scale (i.e., "COVID-19 Clinical Risk Score"), the COVID-19 group scored significantly higher than the non-COVID-19 group, more than four points in the COVID-19 group. All non-COVID patients who did not undergo PCR had a score of 4 or less. CONCLUSIONS: The COVID-19 Clinical Risk Score may enable the risk classification of patients suspected of having COVID-19 and can help in decision-making in clinical practice, including appropriateness of diagnostic testing. Further studies and prospective validation with an increased sample size are required.
  • COVID-19肺炎を合併したCushing病の一例
    高橋 由華; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 湯野 暁子; 澤村 豊; 島津 章; 山下 優; 中久保 祥; 鎌田 啓佑; 鈴木 雅; 今野 哲; 三好 秀明; 渥美 達也
    日本内分泌学会雑誌, 96, 2, 504, 504, (一社)日本内分泌学会, 2020年10月
    日本語
  • 複合免疫不全症の診断を契機に進行性多巣性白質脳症が判明した若年女性の1例
    岩見 昂亮; 松島 理明; 長井 梓; 白井 慎一; 中久保 祥; 岩田 育子; 山田 雅文; 矢部 一郎
    神経治療学, 37, 6, S245, S245, (一社)日本神経治療学会, 2020年10月
    日本語
  • Pneumococcal conjugate vaccine modulates macrophage-mediated innate immunity in pneumonia caused by Streptococcus pneumoniae following influenza.
    Kazuyuki Mimura; Soichiro Kimura; Chiaki Kajiwara; Sho Nakakubo; Matthew A Schaller; Yoshikazu Ishii; Theodore J Standiford; Steven L Kunkel; Kazuhiro Tateda
    Microbes and infection, 22, 8, 312, 321, 2020年09月, [国際誌]
    英語, 研究論文(学術雑誌), Pneumococcal conjugate vaccination (PCV) may prevent influenza-related pneumonia, including Streptococcus pneumoniae pneumonia. To investigate PCV efficacy against secondary pneumococcal pneumonia following influenza, PCV was administered intramuscularly 2 and 5 weeks before S. pneumoniae serotype-3 colonization of murine nasopharynges followed by intranasal challenge with a sublethal dose of influenza A virus. Bacterial and viral loads, including innate immune responses were compared across conditions. PCV vaccination improved the survival of mice with secondary pneumococcal pneumonia and significantly reduced the pulmonary bacterial burden. Increased monocyte/macrophage influx into the lungs, alleviated loss of alveolar macrophages and decreased neutrophil influx into the lungs occurred in PCV-treated mice irrespective of pneumococcal colonization. Higher monocyte chemoattractant protein 1 levels and lower levels of CXCL1, interferon-γ, interleukin-17A, and IL-10, were detected in PCV-treated mice. Additionally, PCV treatment activated the macrophage intracellular killing of S. pneumoniae. Collectively, PCV potentially modulates the host's innate immunity and specific antibodies induction. Macrophage-related innate immunity should be further explored to elucidate the efficacy and mechanisms of PCV versus influenza-related life-threatening diseases.
  • Efficacy of a novel SARS-CoV-2 detection kit without RNA extraction and purification.
    Tatsuya Fukumoto; Sumio Iwasaki; Shinichi Fujisawa; Kasumi Hayasaka; Kaori Sato; Satoshi Oguri; Keisuke Taki; Sho Nakakubo; Keisuke Kamada; Yu Yamashita; Satoshi Konno; Mutsumi Nishida; Junichi Sugita; Takanori Teshima
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 98, 16, 17, 2020年09月, [国際誌]
    英語, 研究論文(学術雑誌), Rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for the diagnosis of coronavirus disease 2019 (COVID-19) and preventing the spread of the virus. A novel detection kit - the 2019 Novel Coronavirus Detection Kit (nCoV-DK) - halves the detection time by eliminating the steps of RNA extraction and purification. We evaluated the concordance between the nCoV-DK and direct PCR. The virus was detected in 53/71 specimens (74.6%) by direct PCR and in 55/71 specimens (77.5%) by nCoV-DK; the overall concordance rate was 94.4%: 95.2% for nasopharyngeal swab, 95.5% for saliva, and 85.7% for sputum. The nCoV-DK test effectively detects SARS-CoV-2 in all types of sample including saliva, while reducing the time required for detection, labor, and the risk of human error.
  • 当科における重症気管支喘息患者に対する生物学的製剤の使用状況
    佐々木 真知子; 清水 薫子; 松本 宗大; 武井 望; 山下 優; 鎌田 啓佑; 中久保 祥; 木村 孔一; 木村 裕樹; 長岡 健太郎; 鈴木 雅; 今野 哲
    日本呼吸器学会誌, 9, 増刊, 279, 279, (一社)日本呼吸器学会, 2020年08月
    日本語
  • 当科における重症気管支喘息患者に対する生物学的製剤の使用状況
    佐々木 真知子; 清水 薫子; 松本 宗大; 武井 望; 山下 優; 鎌田 啓佑; 中久保 祥; 木村 孔一; 木村 裕樹; 長岡 健太郎; 鈴木 雅; 今野 哲
    日本呼吸器学会誌, 9, 増刊, 279, 279, (一社)日本呼吸器学会, 2020年08月
    日本語
  • Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva.
    Sumio Iwasaki; Shinichi Fujisawa; Sho Nakakubo; Keisuke Kamada; Yu Yamashita; Tatsuya Fukumoto; Kaori Sato; Satoshi Oguri; Keisuke Taki; Hajime Senjo; Junichi Sugita; Kasumi Hayasaka; Satoshi Konno; Mutsumi Nishida; Takanori Teshima
    The Journal of infection, 81, 2, e145-e147, 2020年08月, [国際誌]
    英語
  • Older age is associated with sustained detection of SARS-CoV-2 in nasopharyngeal swab samples.
    Takeshi Hattori; Masaru Amishima; Daisuke Morinaga; Keisuke Kamada; Sho Nakakubo; Yu Yamashita; Yasuo Shichinohe; Shinichi Fujisawa; Mutsumi Nishida; Yasuyuki Nasuhara; Takanori Teshima; Satoshi Konno
    The Journal of infection, 82, 1, 159, 198, 2020年06月21日, [国際誌]
    英語
  • Rapidly progressive organizing pneumonia associated with COVID-19.
    Hiroshi Horii; Keisuke Kamada; Sho Nakakubo; Yu Yamashita; Junichi Nakamura; Yasuyuki Nasuhara; Satoshi Konno
    Respiratory medicine case reports, 31, 101295, 101295, 2020年, [国際誌]
    英語, We report a case of clinically diagnosed secondary organizing pneumonia (SOP) associated with coronavirus disease 2019 (COVID-19). A 70-year-old woman who had been diagnosed with COVID-19 was admitted to Hokkaido University Hospital. Although her fever, cough, dyspnea, and serum C-reactive protein levels improved, she developed rapidly progressive respiratory failure and computed tomography revealed the development of bilateral lung consolidation. Her dyspnea was relieved, and her oxygenation levels and radiological findings improved after commencing corticosteroid treatment. Blood biomarkers for interstitial lung disease, Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), showed different responses during the clinical course of her disease. Evaluation of serial changes in levels of KL-6 and SP-D may help diagnose and monitor COVID-19-associated organizing pneumonia (OP). Clinicians should be aware that SOP can develop in response to COVID-19 and that these patients may benefit from the use of steroids.
  • Traditional Japanese Herbal Medicine Hochu-Ekki-to Promotes Pneumococcal Colonization Clearance via Macrophage Activation and Interleukin 17A Production in Mice.
    Sho Nakakubo; Soichiro Kimura; Kazuyuki Mimura; Chiaki Kajiwara; Yoshikazu Ishii; Satoshi Konno; Kazuhiro Tateda
    Frontiers in cellular and infection microbiology, 10, 569158, 569158, 2020年, [国際誌]
    英語, 研究論文(学術雑誌), Streptococcus pneumoniae may colonize the nasopharynx, and as pneumococcal colonization causes invasive diseases and the subsequent transmission, reducing bacterial burden in the nasal cavity is critical. Hochu-ekki-to (TJ-41) is a traditional Japanese herbal medicine that exerts immunomodulatory effects in host cells. In this study, we investigated the potency of TJ-41 in modulating pneumococcal colonization clearance by activating host immunity. Mice, intranasally inoculated with pneumococci, were treated orally with TJ-41. During colonization, TJ-41 treatment significantly reduced pneumococcal burden and increased macrophage population in the nasopharynx. Furthermore, interleukin 17A production was significantly enhanced after TJ-41 treatment. In vitro experiment using nasal-derived cells revealed that pneumococcal antigen exposure upregulated the transcription of interleukin 17A in the TJ-41-treated group compared with that in the control group. Macrophages activated by killed bacteria were significantly increased in the presence of TJ-41 in an interleukin 17A-dependent manner. Moreover, TJ-41 enhanced phagocytosis, inhibited bacterial growth, and improved the antigen-presenting capacity of macrophages. Our results demonstrate that TJ-41 accelerates the clearance of pneumococcal nasopharyngeal colonization via macrophage activation. Subsequent production of interleukin 17A provides an additional benefit to effector cells.
  • A case of primary bacteraemia caused by Salmonella enterica serovar Corvallis in an immunocompetent adult after travel to Southeast Asia
    Sho Nakakubo; Kentaro Nagaoka; Masaru Suzuki; Satoshi Konno; Yasushi Shibue; Tetsuya Ikeda; Masaharu Nishimura
    Access Microbiology, 1, 1, Microbiology Society, 2019年03月01日
    研究論文(学術雑誌), Introduction. Non-typhoidal

    Salmonella

    (NTS) that typically causes diarrhoeal disease in humans has a dramatically more severe and more invasive presentation than typhoid fever in immunocompromised adults. However, the incidence and significance of NTS primary bacteraemia in immunocompetent adults have been unclear.



    Case presentation. A 24-year-old man presented to our hospital with a high fever 14 days after travelling to Vietnam and Cambodia for 14 days. His past medical history, family history and social history were unremarkable, except for his dietary intake history during his stay in Southeast Asia. He did not have any abdominal pain, diarrhoea, enterocolitis, arthritis, or abscesses, as determined by multiple examinations, which included computed tomography. The initial blood cultures identified the presence of Gram-negative bacilli, which were finally identified as the

    Salmonella enterica

    subspecies serovar Corvallis. Thus,

    S. enterica

    serovar Corvallis was the most likely primary bacteria in this patient. Since domestic outbreaks of NTS infections are extremely rare, our case patient was diagnosed with travel-related bacteraemia. The patient had an uneventful recovery after antibiotic administration.



    Conclusion. We report a rare case of bacteraemia caused by

    S. enterica

    serovar Corvallis in an immunocompetent adult after travelling through Vietnam and Cambodia. From the experience of our case, we suggest that more caution is necessary when diagnosing the unique clinical features of travel-related NTS infections.
  • 脳死肺移植の1例
    木野田 直也; 高村 圭; 國崎 守; 中久保 祥; 佐々木 真知子; 荻 喬博; 山本 真; 大竹 節之; 菊地 慶介
    帯広厚生病院医誌, 20, 22, 26, 帯広厚生病院, 2018年01月
    日本語
  • 治療に難渋したCandida guilliermondii菌血症の1例
    鎌田 啓佑; 岡 秀昭; 林 良典; 森島 雅世; 中久保 祥; 荒川 悠; 渋江 寧
    感染症学雑誌, 91, 臨増, 239, 239, (一社)日本感染症学会, 2017年03月
    日本語
  • 明らかな鼠との接触歴がなく、皮疹や関節炎を伴わずに敗血症性ショックを来したStreptobacillus moniliformis菌血症の1例
    鎌田 啓佑; 長岡 健太郎; 中久保 祥; 今野 晢; 西村 正治; 宮川 康宏; 品川 雅明
    感染症学雑誌, 90, 3, 387, 387, (一社)日本感染症学会, 2016年05月
    日本語
  • 肺炎球菌性肺炎における菌血症、非菌血症症例の臨床的差異と、菌血症予測因子に関する検討
    鎌田 啓佑; 長岡 健太郎; 中久保 祥; 今野 哲; 西村 正治
    感染症学雑誌, 90, 臨増, 235, 235, (一社)日本感染症学会, 2016年03月
    日本語
  • NBCAを用いて気管支動脈塞栓術を施行した大量喀血の1例
    吉野 裕紀; 阿保 大介; 高橋 文也; 菊池 穏香; 曽山 武士; 宮本 憲幸; 作原 祐介; 工藤 與亮; 中久保 祥; 在原 房子
    Japanese Journal of Radiology, 34, Suppl., 12, 12, (公社)日本医学放射線学会, 2016年02月
    日本語
  • NBCAを用いて気管支動脈塞栓術を施行した大量喀血の1例
    吉野 裕紀; 阿保 大介; 高橋 文也; 菊池 穏香; 曽山 武士; 作原 祐介; 工藤 與亮; 中久保 祥; 在原 房子
    IVR: Interventional Radiology, 30, 3, 272, 272, (一社)日本インターベンショナルラジオロジー学会, 2015年09月
    日本語
  • 2.2次性肺クリプトコッカス症の1例(第34回 日本呼吸器内視鏡学会北海道支部会)
    正木 慎也; 高村 圭; 武井 望; 山下 優; 中久保 祥; 伊藤 健一郎; 山本 真; 吉川 隆志; 菊地 慶介
    気管支学, 34, 6, 641, 642, 特定非営利活動法人 日本呼吸器内視鏡学会, 2012年
    日本語
■ その他活動・業績
■ 主な担当授業
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
■ 共同研究・競争的資金等の研究課題